Herein, we identified 11 putative actionable biomarkers using the CGI, namely NF1 Q1798*, Q2616*, and S636X, ALK F1174L and R1275Q, SETD2 P10L and Q1829E, BRCA1 R612S, NOTCH1 D1670V, ATR S1372L, and FGFR1 N577K, which were previously reported in NB or any cancer type and are likely to be drug targets of existing or currently being investigated in pre-clinical or clinical trials. This evidence concerns the gene ALK and neuroblastoma.